EP Patent

EP2625176B1 — Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators

Assigned to Xcovery Holdings Inc · Expires 2016-08-17 · 10y expired

What this patent protects

Patent listed against ensartinib-hydrochloride.

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP2625176B1
Jurisdiction: EP
Classification: —
Expires: 2016-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Xcovery Holdings Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.